Altimmune, Inc. (ALT)
Altimmune: Probing Pemvi's MASH Data
Altimmune remains a speculative buy as pemvidutide shows strong Phase IIb MASH results, confirmed by a recent Lancet publication. ALT's pemvidutide demonstrates significant MASH resolution, fibrosis improvement, and favorable safety, differentiating it from competitors and supporting a bullish long-term outlook. Risks include upcoming 48-week binary data, regulatory uncertainty, financial dilution, and heavy competition, but ALT's cash position reduces immediate offering risk.
Altimmune, Inc. (ALT) Q2 2025 Earnings Call Transcript
Altimmune, Inc. (NASDAQ:ALT ) Q2 2025 Earnings Call August 12, 2025 8:30 AM ET Company Participants Gregory L. Weaver - Chief Financial Officer Scott Harris - Corporate Participant Vipin K.
Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect
ALT readies Q2 report as investors await fresh updates on pemvidutide program in obesity and liver disease studies.
Altimmune: Deciphering The MASH Crash (Rating Upgrade)
Despite Altimmune, Inc.'s sharp selloff, I believe the market overreacted to pemvidutide's Phase IIb MASH data, which showed meaningful liver improvements and strong safety. The modest weight loss in MASH patients is not a dealbreaker, as this population is metabolically complex and prior trials in obesity showed competitive efficacy. Pemvidutide's MASH results compare favorably to the only approved drug, Rezdiffra, and could support accelerated approval if efficacy holds in Phase III.
Altimmune: FDA Path Forward Remains Despite Mixed MASH Treatment Data Of Pemvidutide
Altimmune, Inc.'s pemvidutide met the primary endpoint of MASH resolution in phase 2b IMPACT study which sets it on a continued development path going forward. The short 24-week trial duration likely limited fibrosis results; longer studies could achieve statistical significance with this endpoint supporting a continued path for phase 3 development. Pemvidutide uniquely delivers both MASH resolution and weight loss, with the lowest adverse event-related discontinuation rates, giving it strong competitive advantages.
Altimmune shares plunge as MASH drug trial misses key fibrosis endpoint
Shares of Altimmune Inc (NASDAQ:ALT) tumbled 55% on Thursday after the company reported mixed results from a mid-stage trial of its experimental drug pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH). The Phase 2b study met one of its primary endpoints, with pemvidutide achieving statistically significant resolution of MASH without worsening of fibrosis at 24 weeks.
Altimmune: Upcoming MASH Data Could Be High Impact For Business Development Activity
ALT is approach a readout from IMPACT, a phase 2b study of pemvidutide in MASH. MDGL's results with its launch of MASH drug Rezdiffra demonstrate the multi-billion-dollar potential of a MASH drug, although pemvidutide will be compared to other competitors. ALT has also initiated a trial of pemvidutide in alcohol use disorder, with a trial in alcohol liver disease set to start in Q3'25.
How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86%
The mean of analysts' price targets for Altimmune (ALT) points to a 285.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
Valuation always matters in investing. And sometimes you can find stocks that are especially great bargains.
Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine
Altimmune, Inc.'s top-line data from the phase 2b IMPACT study using pemvidutide for the treatment of patients with MASH expected in Q2 of 2025. The global non-alcoholic steatohepatitis [NASH] market could reach $39.3 billion by 2031. Company received IND clearance from the FDA to advance two mid-stage studies using pemvidutide to target patients with AUD and ALD; First phase 2 study to start in mid-2025.
Altimmune to test obesity drug for alcohol use disorder and related health conditions
Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver disease.
Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due Q2
Altimmune's pemvidutide shows promise in treating MASH with obesity, potentially positioning it as a first-in-class drug targeting both liver health and weight loss. Despite past volatility, ALT stock has stabilized, with recent data showing significant weight loss at higher doses, sparking renewed investor interest. Altimmune's Q4 2024 earnings reveal a net loss of $23.2m, with $131.9m in cash, highlighting the company's ongoing financial challenges and reliance on future clinical success.
